Impact of acoustic airflow nebulization on intrasinus drug deposition of a human plastinated nasal cast: New insights into the mechanisms involved by Durand, Marc et al.
Impact of acoustic airflow nebulization on intrasinus
drug deposition of a human plastinated nasal cast: New
insights into the mechanisms involved
Marc Durand, Je´re´mie Pourchez, Ge´rald Aubert, Sandrine Le Guellec,
Laurent Navarro, Vale´rie Forest, Philippe Rusch, Miche`le Cottier
To cite this version:
Marc Durand, Je´re´mie Pourchez, Ge´rald Aubert, Sandrine Le Guellec, Laurent Navarro, et al..
Impact of acoustic airflow nebulization on intrasinus drug deposition of a human plastinated
nasal cast: New insights into the mechanisms involved. International Journal of Pharmacy,
2011, 421 (1), pp.63-71. <10.1016/j.ijpharm.2011.09.023>. <hal-00640705>
HAL Id: hal-00640705
https://hal.archives-ouvertes.fr/hal-00640705
Submitted on 14 Nov 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

 1
Impact of Acoustic Airflow Nebulization on Intrasinus Drug 
Deposition of a Human Plastinated Nasal Cast: New Insights 
into the Mechanisms involved 
 
Marc DURAND  1,2,3 , Jérémie POURCHEZ 2,3,4*,  Gérald AUBERT 5,, Sandrine LE GUELLEC 
6,7
, Laurent NAVARRO 3,4,  Valérie FOREST 2,3,4, Philippe RUSCH 2,3,5,8,9, Michèle COTTIER 
2,3,5,8,9
 
 
 
1
 Centre Hospitalier Emile Roux, F-43012, Le Puy en Velay, France 
 
2
 LINA, Laboratoire Interdisciplinaire d’étude des Nanoparticules Aérosolisées, EA 4624, F-
42023, Saint-Etienne, France 
 
3
 SFR IFRESIS, F-42023, Saint-Etienne, France 
 
4
 Ecole Nationale Supérieure des Mines de Saint-Etienne, Centre Ingénierie et Santé, F-
42023, Saint-Etienne, France 
 
5
 CHU de Saint-Etienne, F-42055, Saint-Etienne, France 
 
6
 DTF-Aerodrug, Faculté de médecine,  F-37032, Tours, France 
 
7
 INSERM-U618, Faculté de Médecine, F-37032, Tours, France 
 
8
 Université Jean Monnet, Faculté de Médecine, F-42023, Saint-Etienne, France 
 
9 Université de Lyon, F-42023, Saint-Etienne, France 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
  Corresponding author:  Tel: (+33) 4 77 42 01 80; Fax: (+33) 4 77 49 96 94;  
                                         E-mail address: pourchez@emse.fr 
 2
ABSTRACT 1 
Purpose: The impact of 100 Hertz (Hz) acoustic frequency airflow on sinus drug deposition 2 
of aerosols was investigated using a human plastinated nasal cast. The influence of drug 3 
concentration and endonasal anatomical features on the sinus deposition enhanced by the 100 4 
Hz acoustic airflow was also examined. 5 
Methods: Plastinated models were anatomically, geometrically and aerodynamically validated 6 
(endoscopy, CT scans, acoustic rhinometry and rhinomanometry). Using the gentamicin as a 7 
marker, 286 experiments of aerosol deposition were performed. Changes of airborne particles 8 
metrology produced under different nebulization conditions (100 Hz acoustic airflow and 9 
gentamicin concentration) were also examined.  10 
Results: Aerodynamic and geometric investigations highlighted a global behaviour of 11 
plastinated models in perfect accordance with a nasal decongested healthy subject. The results 12 
of intrasinus drug deposition clearly demonstrated that the aerosols can penetrate into the 13 
maxillary sinuses. The 100 Hz acoustic airflow led to increase the deposition of drug into the 14 
maxillary sinuses by a factor 2 to 3 depending on the nebulization conditions. A differential 15 
intrasinus deposition of active substance depending on maxillary ostium anatomical features 16 
and drug concentration was emphasized.  17 
Conclusion: The existence of a specific transport mechanism of penetration of nebulized 18 
particles delivered with acoustic airflow was proposed. 19 
Keywords: acoustic airflow, aerosol therapy, drug deposition, plastination, maxillary sinus. 20 
 21 
 22 
 23 
 24 
 25 
 3
1. Introduction 26 
Rhinosinusitis is a significant and increasing health problem which results in a large financial 27 
burden on society (Fokkens et al., 2007). Due to the inflammation of the nasal mucosa or 28 
impaired mucociliary clearance, the blockage of sinus drainage leads to the creation of a 29 
favourable environment for sinusitis. Indeed, under these conditions bacteria and viruses 30 
cannot be removed by secretions drainage and may proliferate. Targeting delivery of 31 
nebulized antibiotics into the maxillary sinuses, the sites of infection, could improve clinical 32 
outcomes in patients with chronic rhinosinusitis. Thus, nasal drug delivery by nebulization is 33 
widely used in sinus disorders, because of its safety and convenience and due to its 34 
advantages as a painless therapy. Topical delivery of antimicrobial drugs for treatment of 35 
rhinosinusitis also brings intuitive advantages over systemic therapy. It minimizes the risk of 36 
systemic side effects, the development of antibiotic resistance in non targeted areas and 37 
allows a high topical drug concentration deposition with a minimal systemic adsorption.  38 
However the nebulization conditions to facilitate penetration of aerosols into the sinus cavities 39 
are not well-established. The practice of aerosol therapy to treat rhinosinusitis has not been 40 
studied thoroughly, despite few works have shown clinical benefit (Vaughan et al., 2002). 41 
The main issue is that it remains very difficult to demonstrate an effective penetration of 42 
aerosolized drugs into paranasal sinuses which are poorly ventilated hollow cavities due to 43 
anatomical features. The maxillary sinuses communicate with the nasal fossa via narrow 44 
ducts: the maxillary ostia (about 1-5 mm in diameter; 10-15 mm in length) (Tarhan et al., 45 
2005). However, some in vivo and in vitro studies have demonstrated that aerosolized 46 
particles can be deposited into paranasal sinuses but always at low concentrations (Hyo et al., 47 
1989; Saijo et al., 2004; Hilton et al., 2008; Durand et al., 2001). These studies highlighted 48 
that the three main factors affecting the aerosol deposition into the maxillary sinuses are: the 49 
diameter/length of the maxillary ostium, the pressure/rate of the aerosol, and finally the 50 
airborne particle size. All things considered, a better understanding of ventilation and drug 51 
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delivery to the maxillary sinuses is required to more accurately define the relevance of nasal 52 
drug delivery for treatment of rhinosinusitis despite the fact it is widely used by the clinicians.  53 
To enhance the penetration of nebulized particles into badly-ventilated areas (i.e. sinuses in 54 
healthy subject) or non-ventilated areas (i.e. sinuses in patients with sinus diseases), a 55 
pressure gradient generated by a acoustic airflow can be added to a usual jet nebulizer 56 
(Guillerm et al., 1959). Few literature citations consider the possible increase in value when 57 
an acoustic pressure wave is added to aerosol. Vecellio et al. recently demonstrated that, 58 
using a nasal sonic jet nebulizer loaded with 99mTc-DTPA in seven healthy male non-59 
smoking volunteers, aerosol deposition in the nasal cavity was 73 ± 10% (% of aerosol 60 
deposited into the airways) (Vecellio et al., 2011). They also highlighted that 5 ± 2% of the 61 
total activity deposited into the nasal cavity was deposited in the maxillary sinuses. Moeller et 62 
al. showed in healthy volunteers a significant increased of 81mKr gas ventilation of the 63 
paranasal sinuses using pulsating airflow (Moeller et al., 2008). These authors also showed 64 
that 6 ± 2% of the total nose deposition reached the sinuses with pulsating aerosol delivery 65 
although less than 1% of this dose penetrated into the sinuses using a nasal pump spray 66 
(Moeller et al., 2010). Similarly, Maniscalco et al. demonstrated that a acoustic airflow 67 
increased the delivery of an aerosolised drug into the paranasal sinuses (Maniscalco et al., 68 
2006). But the gain of intrasinus drug deposition brought by the use of acoustic airflow is 69 
neither well-established nor well-understood. Moreover, the underlying particle transport 70 
mechanism into the sinuses remains misunderstood.  71 
Three main families of human nasal casts can be distinguished to study aerosol deposition: 72 
“pipe models” (Moeller et al., 2008; Maniscalco et al., 2006; Cakmak et al., 2003), plastic 73 
replicas (Schreck et al., 1993; Kelly et al., 2000) and models obtained from cadavers (Hilton 74 
et al., 2008). Unfortunately, the usual experimental casts present some drawbacks or specific 75 
restrictions: “pipe models” may not adequately mimic the anatomy of the human cavity, 76 
plastic replicas can suffer from a lack of thin anatomical details (such as the maxillary ostium 77 
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morphology), and models from cadavers raise issues of time stability and biosecurity. Thus, a 78 
concept of human plastinated nasal cast without any tissue retraction phenomenon was 79 
proposed. Plastination permits the preservation of anatomical specimens in a physical state 80 
approaching that of the living condition. This technique was introduced by Dr. Gunther von 81 
Hagens in late 1970s (von Haggens, 1979). The plastination consists in replacing water and 82 
lipids in biological tissue by curable polymers. The advantages of plastinated nasal specimens 83 
are numerous: anatomical and aerodynamic behaviour close to in vivo, huge time-stability, 84 
water-washability, accessibility of the maxillary sinuses, easy handling, dry odourless, 85 
biologically safe and transportable without constraints.  86 
This study aims at investigating the deposition of aerosols in the maxillary sinuses of a 87 
plastinated human nasal cast presenting dissimilar anatomical features of ostia, with and 88 
without acoustic airflow. The main purpose of this work was to highlight the influence of the 89 
100 Hz acoustic frequency on the sinus drug deposition. To improve our understanding of the 90 
mechanisms involved, the gain of efficiency brought by the 100 Hz acoustic frequency was 91 
also evaluated depending on the gentamicin concentration initially introduced into the 92 
nebulizer and the maxillary ostium anatomical features. Thus, we successively performed 93 
anatomical and aerodynamic characterisations of the plastinated nasal cast, and studied the 94 
metrology of the aerosol (particle size and aerosol output rate) and the acoustic 95 
characterization of the 100 Hz acoustic frequency. Then we conducted 286 experiments of 96 
drug deposition into the maxillary sinuses using various nebulization conditions. 97 
 98 
2. Materials and methods 99 
2.1 Elaboration of plastinated nasal model 100 
A specific plastination technique of cephalic extremities was developed in our laboratory over 101 
the last 10 years in order to obtain nasal casts without any tissue retraction and dedicated to 102 
functional studies (e.g. aerodynamic and aerosol deposition studies) (Durand et al., 2001; 103 
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Croce et al., 2006). In this paper, we focus on a plastinated specimen (Figure 1) obtained from 104 
a deceased man who left his body to the Saint-Etienne Anatomy Laboratory. The plastination 105 
process consists in different successive steps: anatomical sampling, section, fixation, 106 
dissection, dehydration and degreasing, polymer forced impregnation in a vacuum, and then, 107 
curing and polymerization. All these steps were recently described in details in a form that a 108 
lab scientist could follow the procedure and generate an identical cast (Durand et al., 2011). 109 
Last, a specific lateral-paramedian section of the plastinated head was performed to open an 110 
exterior free access to the maxillary sinuses via the cheekbone (Figure 1). Maxillary volumes 111 
and aerodynamic behaviour of the model were nevertheless kept normal. This original 112 
opening allowed the collection and so the quantification of the active drug deposited into 113 
maxillary sinuses during aerosol studies. Technically, two removable plexiglass plates were 114 
used to hermetically close (“closed position” shown in Figure 2 step1), or not (“open 115 
position” shown in figure1B) the maxillary exterior opening during nebulization experiments 116 
and aerodynamic measures.        117 
Legal and ethical principles were strictly respected during the elaboration of plastinated nasal 118 
model. Body donation to science authorizes in France a university to use a cadaver for 119 
teaching and research activities. The different steps of body donation to science are not 120 
governed by the French laws of bioethics, but by several legal and administrative texts. 121 
Before to use a cadaver obtained by donation, an authorization was obtained in which is 122 
clearly defines the usages for research and teaching. The legal’s rules of anonymity were also 123 
complied and the donors were informed on the use of their donation. The respect of the 124 
donors and their families remains a key point of the administration ability to receive these 125 
donations. For all these reasons, the French Research Ethics committees do not have a legal’s 126 
rules to approve the individual research on a cadaver. However the respect of good practices 127 
is frequently checked and valued. 128 
 129 
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2.2 Anatomical and aerodynamic characterization of the plastinated nasal cast 130 
The objective of the characterization work was to evaluate the reliability of nasal cavity 131 
geometry and airflow resistance of the plastinated specimen compared to in vivo data. The 132 
methodologies used to anatomically, geometrically and aerodynamically characterize the 133 
plastinated nasal cast were recently described in details (Durand et al., 2011). A clinical 134 
anatomy study was firstly carried out using CT scans and endoscopy observations. These 135 
techniques were performed on the plastinated model in order to evaluate the preservation of 136 
mucosa in the cast (especially in the middle turbinate area) as well as to precisely define the 137 
geometrical features of the maxillary ostia. The geometry of nasal cavities was also 138 
characterized using acoustic rhinometry. This method is frequently used to determine in vivo 139 
the nasal cross-sectional areas through acoustics reflexion. Each nasal fossa of the plastinated 140 
specimen was separately examined leading to the characterization of the first six centimetres 141 
corresponding to the longitudinal area from the tip of the nostril to the middle meatus region. 142 
As a matter of fact, beyond the sinus ostium region, the acoustic rhinometry overestimates 143 
cross-sectional area and provide no quantitative data for sinus volume or ostium size (Tarhan 144 
et al., 2005).   145 
Aerodynamic assessments were also performed using rhinomanometry providing an objective 146 
quantification of nasal airway resistance. Indeed, rhinomanometry is a well-established and 147 
reliable technique that measures nasal patency in terms of nasal airflow and resistance to 148 
airflow. The measured pressure–flow relationship reflects the functional status of the nasal 149 
airway. We examined separately the resistance of each nasal cavity (in “closed position”) 150 
while the opposite nostril was occluded. Moreover, and for the first time, the serial resistance 151 
of both nasal cavity and ostium was also measured. For example, to measure the airflow 152 
resistance of ostium and nasal cavity on the right side, both nostrils were occluded, and right 153 
sinus cavity was kept in “open position” while the left sinus cavity in “closed position”. These 154 
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original and novel data provide some very important information on the impact of the ostium 155 
morphology on airflow resistance to enter the maxillary sinus cavity.  156 
 157 
2.3 Nebulization system  158 
The nebulization system, including an Atomisor NL11SN jet nebulizer associated with an 159 
AOLH® air source compressor (Diffusion Technique Française, DTF Medical, Saint-Etienne, 160 
France), can produced a “sonic aerosol” by adding a 100 Hz acoustic frequency during 161 
aerosol production. The acoustic frequency was continuously emitted since a vibrating 162 
capsule in the compressor (AS sonic generator, 110 Volts, DTF Medical, Saint-Etienne, 163 
France) and conducted through a 5 mm in width and 1-m in length tube (8.5 mm inside 164 
diameter) to the nebulizer outlet. Nebulizations were performed according to two options 165 
operating mode of the compressor/sonic generator: the classic mode without addition of the 166 
100 Hz acoustic frequency, and the sonic mode with addition of the 100 Hz acoustic 167 
frequency. The nebulizer NL11SN was equiped with a nasal plug (C28 medium size, 168 
Diffusion Technique Française, DTF Medical, Saint-Etienne, France) purchased by the 169 
manufacturer and usually used in clinical practice. This nasal plug ensured the interface 170 
connection between nebulizer and the plastinated model’s nostrils. Depending on the 171 
nebulization experiment, the NL11SN was filled either with 4 mL of a gentamicin solution, or 172 
with 4 mL of NaF 2.5% solution. The nebulizer operates at a flow rate of 8 L.min-1.  173 
 174 
2.4 Acoustic signal of the acoustic airflow 175 
The acoustic pressure waves added to the aerosol during its production by the sonic nebulizer 176 
NL11SN was characterized for a better understanding of its influence on aerosolized particles 177 
deposition in the maxillary sinuses. The acoustic signal coming out of the NL11SN has been 178 
characterized by a usual signal processing methodology, using a digital sound level meter (AZ 179 
Instrument) which measures the maximum acoustic pressure level. The measurements have 180 
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been performed in free field (the distance from the walls was high enough to not influence the 181 
signal’s behaviour and its frequency content) at exactly 1 cm of the output pipe. Besides the 182 
determination of the frequency components of the signal (fundamental amplitude and 183 
potential harmonics) a spectral analysis using the Fourier transform was used.  184 
 185 
2.5 Aerosol metrology 186 
The aim of the metrology study was to determine the impact of the 100 Hz acoustic frequency 187 
on the aerosol output and the particle size. All metrology experiments are summarized in 188 
Table 1. The output of gentamicin aerosol was measured simulating respiration with a 189 
sinusoidal pump and collecting aerosol on a filter. An absolute filter (Inhalation Filter Pad, 190 
Pari GmbH, Germany) was interposed between the nebulizer system and the respiratory pump 191 
(Compas2, Pari GmbH, Germany) which was regulated  according to standard NF EN 13544-192 
1 (i.e. Sinus pattern - Tidal Volume of 500 mL - 15 breath/min - Inspiration:Expiration = 1:1). 193 
The equipments and fluids were stabilized at ambient conditions before use. The nebulizer 194 
system was connected to its associated compressor. Gentamicin was introduced into the 195 
nebulizer. The respiratory pump and compressor were turned on. Nebulization time was 196 
limited to 10 minutes. The amount of gentamicin collected by the filter was determined by a 197 
residual gravimetric method based on weighing dry filters (Vecellio et al., 2004). The output 198 
fraction was obtained by calculating the ratio between the amount of gentamicin collected on 199 
the filter and the amount of gentamicin initially introduced into the nebulizer.  200 
Aerosol particle sizing was defined in terms of Mass Median Aerodynamic Diameter 201 
(MMAD). The MMAD was assessed using cascade impaction according to two 202 
complementary approaches using the NGI (Next Generation pharmaceutical Impactor, Copley 203 
Scientific, USA) and the ELPI (Electrical Low Pressure Impactor, Dekati Ltd, Finland). In 204 
cascade impactors, the aerosolized particles are impacted on different stages depending on 205 
their inertia related to their aerodynamic diameter. These devices allow simultaneous measure 206 
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of the aerodynamic size and of the mass of active drug according to the different size ranges. 207 
The metrology was conducted either with sodium fluoride (NaF; 2.5% wt; 4 mL) a chemical 208 
tracer recommended by European standard procedure (NF EN 13544-1), but also with 209 
gentamicin (40 and 80 mg.mL-1; 4 mL). Unlike the ELPI which was originally designed for 210 
industrial and environmental aerosols, the NGI was specifically designed for pharmaceutical 211 
aerosols and has been included in the British Pharmacopoeia as a test method for the 212 
measurement of aerodynamic particle size distribution (Marple et al., 2004). Thus the NGI 213 
was preferentially used for metrology experiments using gentamicin, because this cascade 214 
impactor was specifically designed to meet the requirements of the US and European 215 
pharmacopeia. The ELPI was preferentially used for metrology experiments using NaF, for its 216 
ability to characterize particle size at a nanometric range, which could be helpful if the 217 
acoustic airflow decreases the aerosol particle size. 218 
The ELPI allows the collection of nebulized particles from 7 nm to 10 µm into 12 size 219 
fractions and operated with an air flow of 10 L.min-1. Prior to each measurement, the 13 ELPI 220 
impaction stages were cleaned. The corona charger was removed. The electrometer range was 221 
set at 400,000 fA, and the baseline was zeroed. The nebulizer was connected to a USP throat 222 
via a PTFE mouthpiece adaptor. The USP throat a 90° bend metal pipe with uniform cross 223 
section slight contractions at the inlet and a small diffuser at the outlet. Nebulizer aerosolized 224 
NaF during 10 minutes, while ELPI V4.0 software recorded current vs. time data for stages 1 225 
to 12. Afterwards, the USP throat, corona charger frame, and each stage were rinsed with 5 226 
mL of deionized water into appropriate volumetric flasks. Liquids were then assayed for 227 
sodium fluoride concentration by electrochemical method indicated by the NF EN 13544-1 228 
procedure (perfectION™ combined F- electrode SevenGo pro™, Mettler Toledo, France). 229 
The MMAD of nebulized particles was calculated according to the standard NF EN 13544-1 230 
using electrochemical measurements of sodium fluoride. The MMAD was interpolated from 231 
the particle size distribution curve by noting the particle size at which the line crosses the 50 232 
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% mark. The geometric standard deviation (GSD) should only be calculated if the particle 233 
size distribution curve was reasonably straight between 10 % and 90 %, showing that the 234 
aerosol was log-normally distributed. Where a straight line is a good fit to the data, the 235 
calculation of GSD was performed by noting the particle size X at which the line crosses the 236 
84.13 % mark, and the particle size Y at which the line crosses the 15.87 % mark. Then the 237 
Geometric Standard Deviation GSD was calculated from the equation X/Y 0.5. 238 
The NGI allows the collection of nebulized particles from 0.98 µm-14.1 µm into 8 size 239 
fractions and operated with an air flow of 15 L.min-1. The amount of gentamicin impacted at 240 
each stage was determined by a residual gravimetric method based on weighing dry filters 241 
(Vecellio et al., 2004). The nebulizer was connected to cascade impactor via the nasal plug in 242 
order to make the measurements in the same nebulization conditions that performed with the 243 
plastinated model. The NGI was cleaned before each experiment. Known weight filters 244 
(Gelmann, Type A/E, VWR international, France) were placed into the plates of the impactor. 245 
The nebulizer equipped with its nasal plug was connected to NGI via the USP. Nasal plug 246 
was used in order to make the measurements in the same nebulization conditions that 247 
performed with the plastinated model. Solution of gentamicin (4 mL, 80 mg/mL or 4 mL, 40 248 
mg/mL) was introduced into the nebulizer and then, vaccum pump and compressor of 249 
nebulizer were turned on. Nebulization time was limited to 10 minutes. After, filters were 250 
collected and placed at ambient temperature for drying. The USP throat was rinsed with 5 mL 251 
of water. Liquid was then placed on a new known weight filter, itself placed with others for 252 
drying step. 24h later all filters were again weighted. The amount of gentamicin impacted on 253 
filters at each stage in correspondence with each cut-off diameters of the NGI was calculated 254 
according to the referred method (Vecellio et al., 2004). Then, MMAD was determined since 255 
the cumulative curve mass vs. size according to European standard method NF EN 13544-1.    256 
 257 
2.6 Drug deposition into the maxillary sinuses 258 
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This study assessed the deposition of an active substance on the walls of the maxillary sinuses 259 
in a plastinated nasal cast. The main objective was to examine the role of the 100 Hz acoustic 260 
frequency on the intrasinus deposition of nebulized drugs. In addition, we wanted to examine 261 
the impact of anatomical features (mainly ostium size) and of initial drug concentration 262 
introduced into the nebulizer on aerosol deposition. To reach these objectives the gentamicin, 263 
an aminoglycoside antibiotic, was used as a marker. We tested both concentrations of 264 
gentamicin (i.e. 40 mg.mL-1 and 80 mg.mL-1), to determine the impact of the active substance 265 
concentration on the aerosol deposition in sinuses. A constant volume of 4 mL of gentamicin 266 
solution was nebulized using the NL11SN jet nebulizer. Nebulizations lasted 10 minutes. 267 
Experiments were performed either with or without acoustic pressure waves at 100 Hz, and 268 
using alternatively a 40 mg.mL-1 or a 80 mg.mL-1 gentamicin solution. 269 
After the nebulization, gentamicin was collected from the maxillary sinuses by flushing with 270 
physiological serum using a syringe containing 1 mL for the right sinus, and 1 mL for the left 271 
sinus (Figure 2). Each sinus was flushed 4 times using the same physiological serum. To 272 
avoid overestimation of the amount of gentamicin deposited into the maxillary sinuses, the 273 
region close to the maxillary ostium was never flushed. Finally, the gentamicin was quantified 274 
in the liquid collected from each maxillary sinus using a fluorescence polarization 275 
immunoassay (FPIA) with TDxFLx analyzer (Abbott Diagnostics Division, USA). The 276 
detection level of the gentamicin dosage was 0.27 mg.L-1. Each sample was assayed 3 times 277 
for each series of measurements and results are expressed as the mean of these 3 values. After 278 
recovery, the plastinated nasal cast was washed copiously with tap water during 10 minutes to 279 
remove all traces of residual gentamicin. Control nebulizations with physiological saline were 280 
randomly performed to verify that the gentamicin content of the flushing liquid collected was 281 
lower than the detection level (and therefore to confirm that the plastinated nasal cast washing 282 
was efficient). Globally, we have analyzed 286 collected liquid for gentamicin concentration 283 
(Table 2). 284 
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The assay reliability is very important in this work as the main conclusions are based around 285 
the deposition of a drug that is quantified. Control nebulizations with physiological saline 286 
emphasize the absence in flushing fluid of any extracts from the cast. Thus all traces of 287 
residual gentamicin were removed after nebulization experiments. Besides, the impact of 288 
matrix effects on overall analytical performance and the potential usability of the data were 289 
determined using a spiked matrix sample. Hence, we used a representative environmental 290 
sample that has known concentration of gentamicin prior to being taken through the entire 291 
analytical process in order to evaluate bias. 1 mL of solution at 2.35 mg.L-1 of gentamicin was 292 
introduced into the maxillary sinuses to simulate an intrasinus drug deposition after 293 
nebulization. The drug recovery efficiency of the methodology used was always in the 85-294 
93% range (i.e we measure a gentamicin concentration between 2 and 2.15 mg.L-1 in the 295 
flushing fluid). These results confirm a good accuracy of the methodology of drug deposition 296 
quantification into the maxillary sinuses. 297 
 298 
2.7 Statistical analysis 299 
Metrologic data obtained from cascade impactors (MMAD) and from output measurements 300 
were analyzed using non-parametric tests. Theses statistical test are adapted to small samples 301 
size and were performed with StatXact software (Cytel, France). Significance was 302 
established with permutation test (p<0.05). 303 
The influence of using sonic mode during nebulization and the influence of gentamicin 304 
concentration on the gentamicin deposition into maxillary sinuses, data obtained from 305 
experiments performed with the plastinated head model were analyzed with t-test (on 306 
XLSTAT software, Addinsoft, USA). A p<0.05 was considered significantly.  307 
 308 
3. Results 309 
3.1 Anatomical features of the plastinated human nasal cast 310 
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The clinical anatomy study by nasofiberoscopy showed that the plastinated nasal specimen 311 
was very similar to living anatomical conditions observed daily by ENT physicians. All 312 
anatomical details were well-preserved. CT scans confirmed the high preservation of the nasal 313 
airway anatomy as well as that of the mucosa of the turbinates (Figure 3). Interestingly, the 314 
plastinated specimen exhibited very dissimilar maxillary ostium morphologies. Indeed, while 315 
the right maxillary sinus ostium appeared as anatomically usual, the left maxillary ostium was 316 
doubtless abnormally short and broad. In particular, the diameter of the left maxillary sinus 317 
ostium was three times higher than that of the right maxillary sinus ostium. However, the 318 
acoustic rhinometry reasonably resolved the airways geometry of the plastinated cast. We 319 
found a perfect symmetry between the left and right nasal cavities with a minimal cross-320 
sectional area around 0.5 cm2 and a cross-sectional area higher than 1.5 cm2 from the middle 321 
meatus region (Figure 4) (Durand et al., 2011).  322 
 323 
3.2 Aerodynamic behaviour of the plastinated human nasal cast 324 
We also measured by rhinomanometry the resistance of each nasal cavity separately while the 325 
opposite nostril was occluded. From the pressure vs. flow curves, the unilateral airflow 326 
resistances found, for left and right nasal cavities, were perfectly similar at 0.18 Pa.s.cm-3 (i.e. 327 
1.8 cmH2O.s.L-1). The bilateral airflow resistance was, logically, lower than unilateral 328 
resistances, around 0.13 Pa.s.cm-3. Finally, very original data were obtained by examining the 329 
airflow serial resistance of both the maxillary ostium and the nasal cavity. Results emphasized 330 
very disparate airflow resistances: 0.73 Pa.s.cm-3 for the left nasal cavity in serial with the left 331 
maxillary ostium, and 1.21 Pa.s.cm-3 for the right nasal cavity in serial with the right 332 
maxillary ostium. Because the uninasal airflow resistances of the left and right nasal cavities 333 
are rigorously identical (0.18 Pa.s.cm-3), this result suggests that morphology changes of the 334 
maxillary ostium could have a huge impact on sinus ventilation. Indeed, the low airflow 335 
resistance put in evidence for the left nasal cavity in serial with the left maxillary ostium is in 336 
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good agreement with the abnormally short and broad ostium of the left maxillary sinus as 337 
determined from CT scans (Figure 3) (Durand et al., 2011).  338 
 339 
3.3 Signal processing of the acoustic airflow 340 
The maximum acoustic pressure level generated at 100 Hz from the NL11SN was equal to 341 
107 dB at 1 cm of the output pipe. The distance of measurement has been empirically chosen 342 
but it allowed relative measurements. Theoretically the signal must be a 100 Hz sinusoidal 343 
signal, but our results highlight that it is not exactly sinusoidal, as shown in Figure 5A. Then, 344 
a spectral analysis using the Fourier transform was performed in order to have a better 345 
understanding of the frequency components of the signal (Figure 5B). The main component of 346 
the signal is 100 Hz as expected, but there are three other harmonic components at 200, 300 347 
and 400 Hz respectively. The fundamental amplitude is about ten times higher than the 348 
harmonics amplitudes. The harmonics are certainly due to the resonance of the pipe which 349 
behaves like a wind instrument. 350 
 351 
3.4 Aerosol metrology 352 
ELPI results using NaF as a marker emphasize a significant decrease of MMAD in presence 353 
of the 100 Hz acoustic airflow of about 35 % (3.45 ± 0.25 µm vs 5.40 ± 0.15 µm). NGI results 354 
using gentamicin as a marker indicate that MMAD significantly increased when the 355 
gentamicin concentration rises (Figure 6). In accordance with ELPI measurements, NGI 356 
results show also that adding the 100 Hz acoustic frequency during nebulization led to 357 
decrease the MMAD for a given gentamicin concentration (Figure 6).  358 
The aerosol output measurements emphasize a huge impact of 100 Hz acoustic frequency. A 359 
significant decrease, about 60%, of the amount of gentamicin aerosolized in presence of 100 360 
Hz acoustic frequency was highlighted (Table 2). Without acoustic pressure waves 17-20 % 361 
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of the volume of gentamicin initially introduced was nebulized, although only 7-8 % was 362 
nebulized in presence of 100 Hz acoustic airflow. 363 
 364 
3.5 Drug deposition into the maxillary sinuses 365 
We sequentially studied the influence of three parameters: the 100 Hz acoustic airflow, the 366 
gentamicin concentration, and the maxillary ostium anatomical features. Results obtained 367 
clearly show that: 368 
 At 80 mg.mL-1, the drug deposition is higher in the left maxillary sinus cavity than in the 369 
right one, either in presence or in absence of acoustic airflow (Figure 7 – Table 3). As a result 370 
the endonasal anatomical features seem to play a major role on aerosol deposition. 371 
 Whatever the initial gentamicin concentration used, the drug deposition in left and right 372 
sinus cavities is higher in presence of 100 Hz acoustic frequency than without acoustic 373 
airflow. We emphasized that the 100 Hz acoustic airflow led to increase at least 2 fold the 374 
drug deposition in the maxillary sinuses for a given maxillary ostium anatomical feature 375 
(Figure 7 – Table 3). 376 
 Both in presence and in absence of acoustic airflow, an increased gentamicin concentration 377 
induced an increased drug deposition in the right as well as in the left maxillary sinuses 378 
(Figure 7 – Table 3). 379 
 380 
4. Discussion 381 
4.1 Influence of 100 Hz acoustic airflow on intrasinus drug deposition 382 
Measurements made using the plastinated nasal cast doubtless highlight that the addition of a 383 
100 Hz acoustic airflow to the gentamicin aerosol leads to a 2 to 3 fold increase drug 384 
deposition into the maxillary sinuses depending on nebulization conditions (Figure 7). 385 
Moreover, it is interesting to examine the gain of drug deposition by the 100 Hz acoustic 386 
airflow comparing the results with and without a 100 Hz acoustic frequency, all other factors 387 
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being exactly the same (i.e. on the same sinus and gentamicin concentration). The gain in 388 
drug deposition brought about by the addition of a 100 Hz acoustic frequency to the aerosol 389 
production is identical, whatever the anatomic and aerodynamic endonasal features, and in 390 
particular, whatever the characteristics of the maxillary ostium (Figure 8). However, this drug 391 
deposition gain is even more important when the initial concentration of gentamicin decreases 392 
(deposition gain of about 100 % at 80 mg.mL-1 vs. a deposition gain of about 220 % at 40 393 
mg.mL-1). As a result, the gain of sinus drug deposition brought by the 100 Hz acoustic 394 
frequency strongly depends on the gentamicin concentration initially introduced into the 395 
nebulizer. 396 
The metrology study indicated that the 100 Hz acoustic frequency significantly reduced the 397 
MMAD of the particles produced by the NL11SN and the aerosol ouput (Figure 6, Table 2). 398 
The decrease of MMAD varies from 10 % to 27 % depending on the initial gentamicin 399 
concentration. In the same time, the decrease of aerosol output is about 60 % whatever the 400 
initial gentamicin concentration. Doubtless, the amount of gentamicin inhaled, for a same 401 
nebulization time, is less important in presence of acoustic airflow since the MMAD and the 402 
aerosol output decrease. However, as the gentamicin concentration collected into maxillary 403 
sinus is greater when nebulization is performed with a 100 Hz acoustic frequency, we suggest 404 
that the amount of particles penetrating into the maxillary sinus is more important in presence 405 
of a 100 Hz acoustic frequency. 406 
Overall, the mechanism underlying the augmentation of drug deposition in presence of 100 407 
Hz acoustic frequency was probably due to a balance between a decrease of particle size and 408 
aerosol output, and an increase of the number of the airborne particles reaching the maxillary 409 
sinuses. 410 
But a key question remains: why does the number of airborne particles reaching the maxillary 411 
sinuses rise in presence of 100 Hz acoustic frequency? A first explanation could be the 412 
smaller particle size induced by the acoustic pressure waves, despite the simultaneous 413 
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decrease of the aerosol output. But in fact, for specific experimental conditions, the rise of 414 
gentamicin concentration can balance the influence of the 100 Hz acoustic frequency on 415 
particle size and on aerosol output. As an example, the MMAD of particles produced by the 416 
NL11SN is almost the same when the 40 mg.mL-1 gentamicin solution is nebulized without 417 
100 Hz acoustic frequency or when the 80 mg.mL-1 gentamicin solution is nebulized with an 418 
acoustic airflow (2.21 ± 0.14 µm and 2.54 ± 0.04 µm respectively). Therefore, if the transport 419 
mechanism for a same particle size was similar in presence or in absence of 100 Hz acoustic 420 
frequency, the amount of gentamicin deposited into the maxillary sinuses when nebulized at 421 
40 mg.mL-1 without a 100 Hz acoustic frequency should be expected to be 1.5-fold higher 422 
(because of the gentamicin concentration is twice while the aerosol output is about 3 times 423 
lower) than the amount deposited during sonic nebulization of 80 mg.mL-1 of gentamicin. 424 
However, the drug deposition rose by a factor 6 to 8. Consequently, for the same particle size, 425 
the presence of acoustic frequency increases by approximately a factor 5 the number of 426 
particles deposited into the maxillary sinuses independently of the acoustic frequency effect 427 
on particle size and aerosol output.  428 
Thus, our results strongly support the existence of a specific transport mechanism of   429 
particles through ostium in the presence of 100 Hz acoustic frequency. Recently, Maniscalco 430 
et al. showed that an oscillating airflow produced by phonation (nasal humming) caused a 431 
large increase in the gas exchange between the nose and the paranasal sinuses (Maniscalco et 432 
al., 2006). Moreover, these authors also demonstrated that the gas ventilation between the 433 
nose and sinuses was even more important when the frequency of the acoustic airflow used 434 
was closed to the resonant frequency of the sinus cavity (Maniscalco et al., 2006-2). In fact, a 435 
cavity of air with an opening will resonate at a natural frequency when the air is excited, as 436 
the well-known principle of the Helmholtz resonator (Kinsler et al., 1962). Indeed, when air is 437 
forced into a cavity, the pressure inside increases. When the external force pushing the air into 438 
the cavity is removed, the higher-pressure air inside will flow out. However, this surge of air 439 
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flowing out will tend to over-compensate, due to the inertia of the air in the neck, and the 440 
cavity will be left at a pressure slightly lower than outside, causing air to be drawn back in. 441 
This process repeats with the magnitude of the pressure changes decreasing each time. All 442 
things considered, we support the conclusion that the sinus cavity could be compared in a first 443 
approximation to a Helmholtz resonator. In this sense, the maxillary sinus can be comparable 444 
to a resonator system that exhibits resonant behaviour in presence of 100 Hz acoustic 445 
frequency. This assumption is in perfect accordance with previous work which estimated the 446 
fundamental resonant frequencies of paranasal sinuses in the range 110-350 Hz using the 447 
Helmholtz resonator theory (Tarhan et al., 2005). 448 
 449 
4.2 Impact of maxillary ostium anatomical and aerodynamical characteristics on drug 450 
deposition 451 
We demonstrated that the aerosols can penetrate into the maxillary sinuses even if we 452 
observed a differential deposition of active substance as a function of maxillary ostium 453 
anatomical features. As a matter of fact the amount of nebulized active substance collected 454 
into the sinus is higher in the left sinus of our plastinated nasal cast. This left sinus was 455 
characterized by a short and broad maxillary ostium inducing a weak airflow resistance to 456 
sinus ventilation. As a result the endonasal anatomic conditions (and the airflow resistance 457 
associated) have certainly a huge impact on drug deposition into maxillary sinuses.  458 
Nevertheless, we also emphasized a significant drug deposition for long and quite narrow 459 
maxillary ostium (right nasal cavity of the plastinated nasal cast). The fact that a small size of 460 
the ostium allows an effective drug deposition is quite encouraging to extrapolate results to 461 
diseased subject. It is obvious that nasal airway obstruction in patients with rhinosinusitis as 462 
well as complete closure of the maxillary ostia prevent any drug deposition into the sinuses. 463 
However, we have the demonstration that aerosols can penetrate into the maxillary sinuses in 464 
the case of quite unfavorable anatomic and aerodynamic endonasal conditions. This result 465 
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seems to be a major value of proving that nebulized drug can reach the middle meatus, which 466 
is considered to be the most common area for sinusitis disorders. In this sense our results 467 
show that the use of 100 Hz acoustic frequency during nebulization may provide sufficient 468 
drug delivery for a topical aerosol therapy in sinonasal disorders. Nevertheless clinical trials 469 
are required to definitively conclude on the clinically efficiency because of the nasal cast 470 
differed from in vivo mainly due to the absence of mucus or breathing with the plastinated 471 
cast. 472 
 473 
5. Conclusion 474 
The plastinated nasal cast appeared useful for in vitro characterization of drug deposition into 475 
maxillary sinuses. We demonstrated that antibiotic aerosol can penetrate into the maxillary 476 
sinuses. We also emphasized a great efficiency of the 100 Hz acoustic airflow to enhance 477 
drug deposition into maxillary sinuses. A significant increase (2 to 3-fold) of intrasinus drug 478 
deposition was obtained in presence of 100 Hz acoustic frequency, despite the decrease of 479 
60% of the aerosol output induced by the acoustic pressure waves. Thus, the acoustic effect 480 
allows the improvement of targeting of nebulized antibiotics to the maxillary sinuses, and 481 
even with the lower concentration of antibiotics nebulized (a great advantage to limit side-482 
effect and to prevent potential antiobiotic resistance). We also established that the addition of 483 
the 100 Hz acoustic frequency reduces the aerodynamic particle size (MMAD). Moreover, the 484 
gain of drug deposition observed in presence of acoustic airflow was independent of the 485 
anatomical and aerodynamical characteristics of the maxillary ostium. These results suggest 486 
that a specific transport mechanism of airborne particle occurs during an acoustic airflow 487 
nebulization. The mechanisms seem to induce a significant rise of the number of particles 488 
penetrating into the maxillary sinus independently of changes on particle size and aerosol 489 
output. The comparison of the sinus cavity to a Helmholtz resonator could, at least partially, 490 
explain the phenomenon observed. Finally, we demonstrated that the gain of drug deposition 491 
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observed with 100 Hz acoustic frequency depends on the gentamicin concentration initially 492 
introduced into the nebulizer. Therefore, this result indicates that specific drug and/or specific 493 
dosages should be selected to fully benefit from the deposition enhancement brought by the 494 
100 Hz acoustic airflow nebulizer.  495 
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Figure 1 1 
 2 
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A B 
 3
Figure 1: Plastinated head model elaborated by a specific plastination procedure and used as a 4 
nasal cast to assess the deposition of drug into the maxillary sinuses. (A) represents the 5 
anterior view and (B) represents the lateral view showing the exterior free access to the left 6 
maxillary sinuses. 7 
8 
 4
 9 
Figure 2 10 
 11 
12 
 5
 13 
Figure 2: Overall description of the drug deposition assessment procedure on the plastinated 14 
nasal cast. 15 
 16 
17 
 6
Figure 3 18 
 19 
20 
 7
 21 
Figure 3: CT scans performed on the plastinated specimen. Observation of the high 22 
preservation of the mucosa and of the different morphology of the maxillary ostia on both 23 
side (white arrows indicate maxillary ostia).24 
 8
 25 
Figure 4  26 
 27 
28 
 9
 29 
Figure 4:  Acoustic rhinometry results obtained on the plastinated nasal cast. 30 
31 
 10 
Figure 5 32 
 33 
 34 
35 
 11 
 36 
 Figure 5: Signal processing of the 100 Hz sound added to the aerosol during its production by 37 
the NL11SN nebulizer / AOLH® compressor / AS sonic generator: shape of the acoustic 38 
signal (A) and spectral analysis using the Fourier transform (B). 39 
 40 
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Figure 6 43 
44 
 13 
 45 
Figure 6: Impact of nebulization conditions (100 Hz acoustic airflow and gentamicin 46 
concentration) on the metrology of airborne particle measured using the NGI impactor 47 
(Permutation test: MMAD without sound pressure waves vs. MMAD with acoustic airflow: p 48 
= 0.0007; MMAD at 40 mg.mL-1 vs. MMAD at 80 mg.mL-1: p = 0.005). 49 
50 
 14 
 51 
Figure 7 52 
53 
 15 
 54 
Figure 7: Influence of a 100 Hz acoustic airflow on the amount of nebulized gentamicin 55 
collected into the maxillary sinuses of the plastinated nasal cast (* : comparisons are 56 
statistically significant). 57 
 58 
59 
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Figure 8 60 
61 
 17 
 62 
Figure 8: Influence of the endonasal anatomical features and the initial gentamicin 63 
concentration introduced into the nebulizer on the sinus deposition gain brought by the 100 64 
Hz acoustic airflow (in comparison with experiments without sound pressure waves). 65 
 66 
 67 
 68 
 69 
 70 
 71 
 72 
 1
Impact of Acoustic Airflow Nebulization on Intrasinus Drug 
Deposition of a Human Plastinated Nasal Cast: New Insights 
into the Mechanisms involved 
 
Marc DURAND  1,2,3 , Jérémie POURCHEZ 2,3,4*,  Gérald AUBERT 5,, Sandrine LE GUELLEC 
6,7
, Laurent NAVARRO 3,4,  Valérie FOREST 2,3,4, Philippe RUSCH 2,3,5,,8,9, Michèle COTTIER 
2,3,5,,8,9
 
 
 
1
 Centre Hospitalier Emile Roux, F-43012, Le Puy en Velay, France 
 
2
 LINA, Laboratoire Interdisciplinaire d’étude des Nanoparticules Aérosolisées, EA 4624, F-
42023, Saint-Etienne, France 
 
3
 SFR IFRESIS, F-42023, Saint-Etienne, France 
 
4
 Ecole Nationale Supérieure des Mines de Saint-Etienne, Centre Ingénierie et Santé, F-
42023, Saint-Etienne, France 
 
5
 CHU de Saint-Etienne, F-42055, Saint-Etienne, France 
 
6
 DTF-Aerodrug, Faculté de médecine,  F-37032, Tours, France 
 
7
 INSERM-U618, Faculté de Médecine, F-37032, Tours, France 
 
8
 Université Jean Monnet, Faculté de Médecine, F-42023, Saint-Etienne, France 
 
9 Université de Lyon, F-42023, Saint-Etienne, France 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*
  Corresponding author:  Tel: (+33) 4 77 42 01 80; Fax: (+33) 4 77 49 96 94;  
                                         E-mail address: pourchez@emse.fr 
 2
Table 1 1 
Nebulization conditions Metrology experiments 
Type of 
marker 
Volume and 
concentration 
With (w) 
or without 
(wo)  
acoustic 
airflow 
ELPI NGI Output 
NaF  4 mL  2.5% wt w   n=3   
NaF  4 mL  2.5% wt wo n=3   
Gentamicin  4 mL  40 mg.mL-1 w  n = 3 n=3 
Gentamicin  4 mL  40 mg.mL-1 wo  n = 3 n=3 
Gentamicin  4 mL  80 mg.mL-1 w  n = 3 n=3 
Gentamicin  4 mL  80 mg.mL-1 wo  n = 3 n=3 
 2 
3 
 3
 4 
Table 1: Design of the metrology experiments conducted during the study. 5 
6 
 4
 7 
Table 2 8 
Nebulization 
conditions Type of nebulization 
Number of 
experiments 
(gentamicin dosage) 
Aerosol output 
results 
Control nebulization 
with physiological 
saline solution             
(4 mL without 
gentamicin)  
10 minutes 
nebulization  66 - 
Gentamicin solution  
(4 mL at 40 mg.mL-1) 
10 minutes 
nebulization  
“classic” operating 
mode 
62 0.83 ± 0.05 mL 
Gentamicin solution   
(4 mL at 40 mg.mL-1) 
10 minutes 
nebulization  
“sonic” operating 
mode 
54 0.32 ± 0.02 mL 
Gentamicin solution   
(4 mL at 80 mg.mL-1) 
10 minutes 
nebulization  
“classic” operating 
mode 
68 0.68 ± 0.04 mL 
Gentamicin solution   
(4 mL at 80 mg.mL-1) 
10 minutes 
nebulization  
“sonic” operating 
mode 
36 0.30 ± 0.02 mL 
 9 
10 
 5
Table 2: Design of the drug deposition experiments conducted on the plastinated nasal cast 11 
and results of the aerosol output measurements. “sonic” operating mode corresponds to 12 
nebulization with 100 Hz acoustic airflow. “classic” operating mode corresponds to 13 
nebulization without acoustic pressure waves. 14 
15 
 6
Table 3 16 
 
40 mg/mL 
left sinus 
40 mg/mL 
right sinus 
80 mg/mL 
left sinus 
80 mg/mL 
right sinus 
40 mg/mL 
left sinus 
acoustic 
airflow 
40 mg/mL 
right sinus 
acoustic 
airflow 
80 mg/mL 
left sinus 
acoustic 
airflow 
40 mg/mL - right sinus p = 0.679       
80 mg/mL - left sinus * p < 0.0001       
80 mg/mL - right sinus 
 
* 
p < 0.0001 
* 
p = 0.005     
40 mg/mL - left sinus 
acoustic airflow 
* 
p < 0.0001       
40 mg/mL - right sinus 
acoustic airflow  
* 
p < 0.0001   p= 0.242   
80 mg/mL - left sinus 
acoustic airflow   
* 
p = 0.0005  
* 
p < 0.0001   
80 mg/mL - right sinus 
acoustic airflow    
* 
p = 0.002  
* 
p = 0.001 
* 
p = 0.019 
 17 
18 
 7
 19 
Table 3: Statistical analysis of gentamicin aerosol deposition into the maxillary sinuses of the 20 
plastinated nasal cast. Light grey: impact of a 100 Hz acoustic airflow; grey: impact of the 21 
initial gentamicin concentration introduced into the nebulizer, dark grey: impact of endonasal 22 
anatomical features (disparate size and morphology of left and right ostia). 23 
 24 
